The ALS Functional Rating Scale (ALSFRS) is a validated rating instrument for monitoring the progression of disability in patients with amyotrophic lateral sclerosis (ALS). One weakness of the ALSFRS as origina
并且伦敦分期具有简单易行的特点,其评分方法不依赖于改良的ALS功能评分量表(ALS functional rating scale~.revised,ALSFRS-R),通过患者近期临床表现即可判断,故可由一系列具有不同经验水平的卫生保健专业人员前瞻性地使用【19】,具有良好的应用前景。有研究将ALSFRS-R与伦敦分期进行比较,表明两种评估方法具有良好一致性,...
应用DTI技术研究发现ALS患者在皮质脊髓束、放射冠、内囊后肢等结构各向异性分数(fractional anisotropy, FA)值降低。此外,研究表明皮质脊髓束FA值与修订版ALS功能评分量表(Revised ALS Functional Rating Scale, ALSFRS-R)之间存在相关性。然而,先前的研究主要集...
WM 损伤主要影响 CST 和其他运动相关区域,如放射冠、内囊后肢、中脑、延髓和胼胝体中部。DTI 研究显示,CST、胼胝体、扣带束和额叶及前额叶区域的 FA 值降低,且 CST 中 FA 的降低与疾病进展和修订的 ALS 功能评定量表(Revised ALS Functional Rating Scale,ALSFRS-R)显著相关。 随着疾病进展,WM 变化从运动区扩散...
DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients ...
在主要评估指标方面,即修订的肌萎缩侧索硬化症功能评定量表(Revised Amyotrophic Lateral Sclerosis Functional Rating Scale,ALSFRS - R)评分从基线的变化情况,研究发现,阿瑞莫克隆组与安慰剂组相比,差异并不具有统计学意义(MD = 0.4495;95% CI: - 0.39,1.27;p = 0.30)。这意味着从这个关键指标来看,阿瑞莫克隆...
指南由该协会2014年“冰桶挑战赛”获得的资金支持。该指南在2018年发布草案后,又在2019年发布了定稿指南。FDA强烈建议申办人开展随机、安慰剂对照、双盲研究。一般而言,ALS药物的有效性应通过日常活动中对功能的治疗效果的证明来确定,其中包括ALSFRS-R(ALS Functional Rating Scale-Revised)或类似的评分方法。
The ALS Functional Rating Scale Revised (ALSFRS-R) score is a patient-reported, clinician-assessed, 48-point scale measuring overall functional status. The total score had a variable range at screening (mean 36, range 29–40), and participants progressed at a mean rate of 1.2 points per mont...
Data from clinical studies show that NeuroNata-R slows the progression of ALS as measured by a change in ALS Functional Rating Scale-Revised (ALSFRS-R)2,3. A phase 1 open-label study demonstrated the safety and feasibility of two repeated intrathecal injections of autologous bone marrow-derived...
ALS Functional Rating Scale Revised (ALSFRS-R) and %Forced Vital Capacity (%FVC) were also evaluated before and after therapy. Results: Eleven patients underwent 1 course, and three under- went 3 courses of therapy. There were no dropouts and severe adverse effect. To evaluate the effect of...